UCB : Une recovery qui se confirme
>Un S1 rassurant pour atteindre le haut de la fourchette de guidance 2024 - UCB publiait hier des résultats du S1 très solides alors que nous anticipions un point plus bas (-12% à tcc) du fait de sa base de comparaison et du lancement de Bimzelx. Ce dernier représente notamment la bonne surprise de cette publication. Les extensions d’indication européennes et l’évolution de la prise en charge aux Etats-Unis ont permis de faire ressortir des ventes au-delà de nos espé...UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.